Alan Ashworth

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Alan Ashworth
Born 1960 (age 57–58)
Bolton, Lancashire
Nationality British
Alma mater
Scientific career
Thesis Cloning and characterisation of cDNAs derived from cytochrome P-450 mRNAs (1984)
Doctoral students Elizabeth Iorns[citation needed]

Alan Ashworth, FRS (born 1960 in Bolton, Lancashire) is a British molecular biologist, noted for his work on genes involved in cancer susceptibility. He is currently the President of the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, a multidisciplinary research and clinical care organisation that is one of the largest cancer centres in the Western United States.[1] He was previously CEO of the Institute of Cancer Research (ICR) in London.[2]

Early life[edit]

Ashworth was educated at St Mary's Primary School and Thornleigh Salesian College, Bolton. He completed his Bachelor of Science in Chemistry and Biochemistry at Imperial College, London, and was awarded a PhD in Biochemistry at University College, London.[3]


Ashworth joined the Institute for Cancer Research (ICR) in London in 1986 as a Postdoctoral research Scientist in the Section of Cell and Molecular Biology and in 1999 he was appointed the first Director of the Breakthrough Breast Cancer Research Centre (BBCRC).[4] The Centre is now recognised internationally and has more than 120 scientists and researchers working on aspects of the disease ranging from basic molecular and cellular biology through to translational research and clinical trials.[4] Ashworth's Directorship ended in January 2011 when he took up the position of Chief Executive of the ICR which he held until December 2014.[5]

One of Ashworth's major contributions to cancer research has been his work on genes involved in cancer risk. He was a key part of the team that in 1995 discovered the BRCA2 gene,[6][7][8][9] which is linked to an increased risk of some types of cancers[10]/ which is now used to identify women at high risk of the disease. Ten years later, Ashworth identified a way to exploit genetic weaknesses in cancer cells including mutated BRCA 1 or BRCA2, leading to a new approach to work on Poly ADP ribose polymerase (PARP as a drug target for cancer.[11][12]

Ashworth's research and leadership reflects his passion for translating laboratory studies into improvements in patient care, particularly by the development of personalised cancer medicine.[13][14]

In 2014, Ashworth stepped down as Director of the ICR to join the University of California, San Francisco as President of the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC) and Senior Vice-President of Cancer Services of UCSF Health from January 2015.[15] He also serves as Professor of Medicine, Division of Hematology/Oncology, Department of Medicine and holds the E. Dixon Heise Distinguished Professorship in Oncology.[16]

In 2016, Ashworth and Pamela Munster, MD, established the UCSF Center for BRCA Research. In November 2016 he started the San Francisco Cancer Initiative (SF CAN). In 2017, he became inaugural chair of the University of California Cancer Consortium.

Awards and recognition[edit]


  1. ^ "Research profiles: Professor Alan Ashworth FRS". UCSF Helen Diller Family Comprehensive Cancer Center. 
  2. ^ "Management structure". The Institute of Cancer Research. Archived from the original on 2011-06-10. Retrieved 2011-06-12. 
  3. ^ [1][dead link]
  4. ^ a b [2][dead link]
  5. ^ [3][dead link]
  6. ^ Roth, S; Kristo, P; Auranen, A; Shayehgi, M; Seal, S; Collins, N; Barfoot, R; Rahman, N; Klemi, P. J.; Grénman, S; Sarantaus, L; Nevanlinna, H; Butzow, R; Ashworth, A; Stratton, M. R.; Aaltonen, L. A. (1998). "A missense mutation in the BRCA2 gene in three siblings with ovarian cancer". British Journal of Cancer. 77 (8): 1199–202. doi:10.1038/bjc.1998.202. PMC 2150153Freely accessible. PMID 9579822. 
  7. ^ Connor, F; Smith, A; Wooster, R; Stratton, M; Dixon, A; Campbell, E; Tait, T. M.; Freeman, T; Ashworth, A (1997). "Cloning, chromosomal mapping and expression pattern of the mouse Brca2 gene". Human Molecular Genetics. 6 (2): 291–300. doi:10.1093/hmg/6.2.291. PMID 9063750. 
  8. ^ Bignell, G; Micklem, G; Stratton, M. R.; Ashworth, A; Wooster, R (1997). "The BRC repeats are conserved in mammalian BRCA2 proteins". Human Molecular Genetics. 6 (1): 53–8. doi:10.1093/hmg/6.1.53. PMID 9002670. 
  9. ^ Lancaster, J. M.; Wooster, R; Mangion, J; Phelan, C. M.; Cochran, C; Gumbs, C; Seal, S; Barfoot, R; Collins, N; Bignell, G; Patel, S; Hamoudi, R; Larsson, C; Wiseman, R. W.; Berchuck, A; Iglehart, J. D.; Marks, J. R.; Ashworth, A; Stratton, M. R.; Futreal, P. A. (1996). "BRCA2 mutations in primary breast and ovarian cancers". Nature Genetics. 13 (2): 238–40. doi:10.1038/ng0696-238. PMID 8640235. 
  10. ^ Wooster, R.; Bignell, G.; Lancaster, J.; Swift, S.; Seal, S.; Mangion, J.; Collins, N.; Gregory, S.; Gumbs, C.; Micklem, G.; Barfoot, R.; Hamoudi, R.; Patel, S.; Rices, C.; Biggs, P.; Hashim, Y.; Smith, A.; Connor, F.; Arason, A.; Gudmundsson, J.; Ficenec, D.; Kelsell, D.; Tonin, P.; Timothy Bishop, D.; Spurr, N. K.; Ponder, B. A. J.; Eeles, R.; Peto, J.; Devilee, P.; Cornelisse, C. (1995). "Identification of the breast cancer susceptibility gene BRCA2". Nature. 378 (6559): 789–792. doi:10.1038/378789a0. PMID 8524414. 
  11. ^ Cressey, D (2010). "Translational research: Talking up translation: Alan Ashworth took a cancer drug from Petri dish to patients in near record speed". Nature. 463 (7280): 422–3. doi:10.1038/463422a. PMID 20110964. 
  12. ^ Wooster, R.; Neuhausen, S.; Mangion, J.; Quirk, Y.; Ford, D.; Collins, N.; Nguyen, K.; Seal, S.; Tran, T.; Averill, D.; Et, A. (1994). "Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13". Science. 265 (5181): 2088–2090. doi:10.1126/science.8091231. PMID 8091231. 
  13. ^ Cressey, Daniel (27 January 2010). "Translational research: Talking up translation". Nature News. 463 (7280): 422–423. doi:10.1038/463422a. Retrieved 4 October 2017 – via 
  14. ^ "Breakthrough Generations". Retrieved 4 October 2017. 
  15. ^ "Acclaimed British Scientist Alan Ashworth Is Named Director of the UCSF Helen Diller Family Comprehensive Cancer Center". University of California, San Francisco. Archived from the original on 2015-04-02. 
  16. ^ "Alan Ashworth, PhD, FRS - UCSF Helen Diller Family Comprehensive Cancer Center". Retrieved 4 October 2017. 
  17. ^ "Find an EMBO member (searchable database of members)". EMBO. Archived from the original on 2011-07-22. Retrieved 2011-06-12. 
  18. ^ "Fellows: Professor Alan Ashworth FRS FMedSci". The Academy of Medical Science. Archived from the original on 2011-08-20. Retrieved 2011-06-12. 
  19. ^ "New Fellows 08 Agarwal – Cohen – New Fellows 2008 – The Royal Society". The Royal Society. Archived from the original on 2011-08-11. Retrieved 2010-01-27. 
  20. ^ "awardees". ESMO. Archived from the original on 2011-08-29. Retrieved 2011-06-12. 
  21. ^ "Directory of Fellows". European Academy of Cancer Sciences. Archived from the original on 2012-03-25. 
  22. ^ "Press release: Alan Ashworth To Receive Award for His Breakthrough Work in Breast Cancer". Samuel Waxman Cancer Research Foundation. 
  23. ^ "2010 Meyenburg Award for Discoverer of BRCA 2 Breast Cancer Gene". Retrieved 4 October 2017. 
  24. ^ "Penn's Basser Research Center for BRCA Names UK Breast Cancer Researcher Alan Ashworth Winner of First Annual Basser Global Prize – PR News". Retrieved 4 October 2017. 
  25. ^ "Ashworth Receives Award from Cancer Nonprofit". UC San Francisco. Retrieved 4 October 2017. 
  26. ^ "International Symposium on Molecular Medicine & Infectious Disease Prize Winners - College of Medicine". Retrieved 4 October 2017. 
  27. ^ "Board of Directors". Retrieved 4 October 2017. 
  28. ^ {{cite web|url= Awards||accessdate=15 December 2017}}

External links[edit]